November 8, 2019 8:28am
While “our” universe of cell and gene therapy are “stuck” in earnings season and the LPS (loss-per-share) shuffle ain’t over, although we are half way through
A factoid, volume remains low as percentage (%) moves vacillate
My version of the morning’s numbers is written to be informative than just about changes to fundamentals; it’s what happened or will beyond the headline and what could happen to the future
Ask yourself, do you know why you own certain equity? What’s been communicated re a company’s status at any given time to shareholders other than quarterly reports or a once-upon-a-time press release!
Dow futures are UP +0.03% (+8 points), S&P futures are DOWN -0.06% (-2 points) and NASDAQ futures are DOWN -0.14% (12 points)
U.S. stock index futures vibrated following Thursday’s record close for the Dow;
European markets move lower amid trade worries;
Asia Pacific stocks are lower as investors digest US-China trade developments;
Data Docket: consumer sentiment figures out at 10 a.m. ET as well as wholesale trade numbers.
Cell and gene therapy stocks rose on Thursday after the world’s two largest economies reportedly agreed to remove existing trade tariffs, sparking a rotation into equities and out of bonds.
So what is next, a slight retrenchment?
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators rollercoaster:
• Thursday the IBB closed up +0.04% while the XBI closed up +0.21%
• Wednesday the IBB closed down -1.21% while the XBI closed down -1.42%
• Tuesday the IBB closed up +0.02% while the XBI closed flat at 0.00%
• Monday the IBB closed down -0.35% while the XBI closed down -0.53%
Thursday night’s newsletter heading: “the sector bounced to the upside as momentum moved on trade deal optimism.”
Review the content for the context of today’s market: https://www.regmedinvestors.com/articles/11095
- November has registered 3 positive and 2 negative close
- October registered 10 positive, 1 neutral and 14 negative closes
- September, there were 1 holiday, 11 negative, 7 positive and 2 non reported sessions;
Companies in my headlights – It’s your decision; I provide an idea and context:
*** I can’t change my “tune” … be mindful of upcoming quarterly results and their effect upon share pricing … BUY and get trampled in the coming sessions or SELL into strength or just HOLD and wait to resolve relieve the earnings estimates and expectation anxiety.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.